Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 228-235

  Roelofs, Anke J ^a,b,e   Edwards, Claire M ^c   Russell, R Graham G ^a   Ebetino, F Hal ^d   Rogers, Michael J ^b   Hulley, Philippa A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; FARNESOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; MEVINOLIN; PHOSPHATIDYLCHOLINE; PROTEIN; RAP1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; MYELOMA CELL; PRENYLATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DIPHOSPHONATES; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MEVALONIC ACID; MULTIPLE MYELOMA; PHOSPHATIDYLCHOLINES; PROTEIN ISOPRENYLATION;

EID: 34250708500     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.116467     Document Type: Article

References (40)

1. Alberts DS, Hallum AV 3rd, Stratton-Custis M, Garcia DJ, Gleason-Guzman M, Salmon SE, Santabarbara P, Niesor EJ, Floret S, and Bentzen CL (2001) Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin Cancer Res 7:1246-1250.
2. Anthony ML, Zhao M, and Brindle KM (1999) Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J Biol Chem 274:19686-19692.
3. Berkhout TA, Simon HM, Jackson B, Yates J, Pearce N, Groot PH, Bentzen C, Niesor E, Kerns WD, and Suckling KE (1997) SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis. Atherosclerosis 133:203-212.
4. Bonate PL, Floret S, and Bentzen C (2004) Population pharmacokinetics of apomine: a meta-analysis in cancer patients and healthy males. Br J Clin Pharmacol 58:142-155.
5. Brown MS, Faust JR, and Goldstein JL (1978) Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253:1121-1128.
6. Brown MS and Goldstein JL (1980) Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21:505-517.
7. Conte P and Coleman RE (2004) Bisphosphonates in the treatment of skeletal metastases. Semin Oncol 31:59-63.
8. Correll CC, Ng L, and Edwards PA (1994) Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 269:17390-17393.
9. Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, and Rogers MJ (2005) Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 37:349-358.
10. Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D, McKinnon AD, Nesbitt SA, Horton MA, Seabra MC, et al. (2001) Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 276:48213-48222.
11. Crick DC, Andres DA, and Waechter CJ (1997) Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun 237:483-487.
12. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, and Penn LZ (2001) Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 7:158-167.
13. Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Russell RG, Van Camp B, Guyon-Gellin Y, Niesor EJ, Bentzen GL, et al. (2007) Apomine, an inhibitor of HMG-CoA reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int J Cancer 120:1657-1663.
14. Flach J, Antoni I, Villemin P, Bentzen C, and Niesor EJ (2000) The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. Biochem Biophys Res Commun 270:240-246.
15. Graaf MR, Richel DJ, Van Noorden CJ, and Guchelaar HJ (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30:609-641.
16. Gutierrez GE, Lalka D, Garrett IR, Rossini G, and Mundy GR (2006) Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos Int 17:1033-1042.
17. Haug JS, Goldner CM, Yazlovitskaya EM, Voziyan PA, and Melnykovych G (1994) Directed cell killing (apoptosis) in human lymphoblastoid cells incubated in the presence of farnesol: effect of phosphatidylcholine. Biochim Biophys Acta 1223:133-140.
18. Istvan ES and Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160-1164.
19. Jackson B, Gee AN, Guyon-Gellin Y, Niesor E, Bentzen CL, Kerns WD, and Suckling KE (2000) Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1- diphosphonate (SR-9223i). Arzneim-Forsch 50:380-386.
20. Kanis JA and McCloskey EV (2000) Bisphosphonates in multiple myeloma. Cancer 88:3022-3032.
21. Lowe LC, Senaratne SG, and Colston KW (2005) Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activation. Biochem Biophys Res Commun 329:772-779.
22. Luckman SP, Hughes DE, Coxon FP, Russell RGG, and Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589.
23. Melnykovich G, Haug JS, and Goldner CM (1992) Growth inhibition of leukemia cell line CEM-C1 by farnesol: effects of phosphatidylcholine and diacylglycerol. Biochem Biophys Res Commun 186:543-548.
24. Miquel K, Pradines A, Tercé F, Selmi S, and Favre G (1998) Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J Biol Chem 273:26179-26186.
25. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, and Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949.
26. Nakanishi M, Goldstein JL, and Brown MS (1988) Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase: mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J Biol Chem 263:8929-8937.
27. Nguyen L, Niesor E, Phan H, Maechler P, and Bentzen C (1991) inventors; Symphar S.A., assignee. Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them. U.S. patent 5,043,330. 1991 Aug 27.
28. Niesor EJ, Flach J, Lopes-Antoni I, Perez A, and Bentzen C (2001) The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des 7:231-259.
29. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, and Takayanagi R (2001) Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 287:337-342.
30. Ramachandra S and Studzinsky GP (1995) Morphological and biochemical criteria of apoptosis, in Cell Growth and Apoptosis: A Practical Approach (Studzinsky GP ed) pp 119-142, Oxford University Press, Oxford, UK.
31. Roelofs AJ, Hulley PA, Meijer A, Ebetino FH, Russell RG, and Shipman CM (2006) Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer 119:1254-1261.
32. Roitelman J, Masson D, Avner R, Ammon-Zufferey C, Perez A, Guyon-Gellin Y, Bentzen CL, and Niesor EJ (2004) Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity. J Biol Chem 279:6465-6473.
33. Sever N, Song BL, Yabe D, Goldstein JL, Brown MS, and DeBose-Boyd RA (2003) Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. J Biol Chem 278:52479-52490.
34. Shipman CM, Croucher PI, Russell RG, Helfrich MH, and Rogers MJ (1998) The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58:5294-5297.
35. Sinensky M, Beck LA, Leonard S, and Evans R (1990) Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 265:19937-19941.
36. Sleijfer S, Van der Gaast A, Planting AS, Stoter G, and Verweij J (2005) The potential of statins as part of anti-cancer treatment. Eur J Cancer 41:516-522.
37. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, et al. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483-491.
38. van de Donk NW, Kamphuis MM, van Kessel B, Lokhorst HM, and Bloem AC (2003) Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 102:3354- 3362.
39. Voziyan PA, Goldner CM, and Melnykovich G (1993) Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing cholinephosphotransferase activity. Biochem J 295:757-762.
40. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, and Hommel U (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692.